Related Experiment Video

Updated: Jul 12, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Protein kinases as targets for cancer treatment

Georgios Giamas1, Justin Stebbing, Constantinos E Vorgias

  • 1Clinic of General-, Visceral- and Transplantation Surgery, University of Ulm, 89075 Ulm, Germany.

Pharmacogenomics
|August 25, 2007
PubMed

Insights

New small-molecule kinase inhibitors show promise for cancer treatment, offering targeted therapy with improved efficacy and reduced toxicity compared to conventional methods.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Conventional cancer therapies like chemotherapy, radiation, and surgery often have limited efficacy and significant side effects.
  • Recent scientific advances have identified cancer-specific molecular targets and signaling pathways.
  • Targeted therapies offer enhanced selectivity, efficacy, and reduced toxicity for cancer treatment.

Purpose of the Study:

  • To review new small-molecule inhibitors targeting protein kinases in cancer.
  • To discuss the specificity, mechanism of action, and antitumor activity of these inhibitors.

Main Methods:

  • Review of scientific literature on small-molecule kinase inhibitors.
  • Analysis of data on specificity, mechanism of action, and antitumor effects.
  • Discussion of tyrosine and serine/threonine kinase inhibitors.

Main Results:

  • Protein kinases are validated molecular targets for cancer therapy.
  • Small-molecule kinase inhibitors demonstrate positive effects in clinical studies.
  • New inhibitors exhibit specificity and antitumor activity.

Conclusions:

  • Kinase inhibitors represent a promising targeted approach for cancer treatment.
  • These targeted drugs offer improved efficacy and reduced toxicity.
  • Further research into kinase inhibitors is warranted for cancer therapy.

More Related Videos

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Protein Networks02:26

Protein Networks

An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...